Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon (E.C. Parish & Rchb. f) Hook. f A new phenanthrene, 9,10-dihydro-4-(4′-hydroxybenzyl)-2,5-dimethoxyphenanthrene-1,7-diol (1) and three known phenanthrenes i.e., 1-(4′-hydroxybenzyl)-4,8-dimethoxyphenanthrene-2,7-diol (2), (9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol (3) and 1,5,7-trimethoxyphenanthrene-2,6-diol) (4) were isolated. Among these, 2 was the most potent PDE5 inhibitor (IC50 =1.67±0.54 μM) evaluated by the [3H]cGMP radioassay method, whereas 1 showed mild activity (IC50 = 62.3±3.3 μM). Their inhibitory selectivities against PDE5 over PDE6 were also studied. This study suggests phenanthrenes as a new class of PDE5 inhibitors.
DiazVA, CloseJD. (2010) Male sexual dysfunction. Primary Care: Clinics in Office Practice, 37, 473–489.
2.
HatzimouratidisK, AmarE, EardleyI, GiulianoF, HatzichristouD, MontorsiF, VardiY, WespesE. (2010) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Urology, 57, 804–814.
3.
WylieK, KenneyG. (2010) Sexual dysfunction and the ageing male. Maturitas, 65, 23–27.
4.
ShamloulR, GhanemH. (2013) Erectile dysfunction. The Lancet, 381, 153–165.
5.
SelvinE, BurnettAL, PlatzEA. (2007) Prevalence and risk factors for erectile dysfunction in the US. The American Journal of Medicine, 120, 151–157.
6.
AytacI, McKinlayJ, KraneR. (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU International, 84, 50–56.
7.
de JesusC, PassosXS, SantosFB, FariaEB, MacielT. (2016) The prevalence of erectile dysfunction in the Brazilian male population. World Journal of Pharmacy and Pharmaceutical Sciences, 5, 1903–1914.
8.
BrockG. (2002) Oral agents: first-line therapy for erectile dysfunction. European Urology Supplements, 1, 12–18.
9.
MontorsiF, BrigantiA, SaloniaA, RigattiP, BurnettAL. (2006) Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?European Urology, 49, 979–986.
10.
DiazVA, CloseJD. (2010) Male sexual dysfunction. Primary Care: Clinics in Office Practice, 37, 473–489.
11.
HatzimouratidisK, AmarE, EardleyI, GiulianoF, HatzichristouD, MontorsiF, VardiY, WespesE. (2010) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Urology, 57, 804–814.
12.
WylieK, KenneyG. (2010) Sexual dysfunction and the ageing male. Maturitas, 65, 23–27.
13.
ShamloulR, GhanemH. (2013) Erectile dysfunction. The Lancet, 381, 153–165.
14.
SelvinE, BurnettAL, PlatzEA. (2007) Prevalence and risk factors for erectile dysfunction in the US. The American Journal of Medicine, 120, 151–157.
15.
AytacI, McKinlayJ, KraneR. (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU International, 84, 50–56.
16.
de JesusC, PassosXS, SantosFB, FariaEB, MacielT. (2016) The prevalence of erectile dysfunction in the Brazilian male population. World Journal of Pharmacy and Pharmaceutical Sciences, 5, 1903–1914.
17.
BrockG. (2002) Oral agents: first-line therapy for erectile dysfunction. European Urology Supplements, 1, 12–18.
18.
MontorsiF, BrigantiA, SaloniaA, RigattiP, BurnettAL. (2006) Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?European Urology, 49, 979–986.
19.
MorelandRB, GoldsteinI, KimNN, TraishA. (1999) Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: research and clinical implications in erectile dysfunction. Trends in Endocrinology & Metabolism, 10, 97–104.
20.
BurkeRM, EvansJD. (2012) Avanafil for treatment of erectile dysfunction: review of its potential. Vascular Health and Risk Management, 8, 517–523.
21.
RashidA. (2005) The efficacy and safety of PDE5 inhibitors. Clinical Cornerstone, 7, 47–55.
22.
GoldenbergMM. (1998) Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clinical Therapeutics, 20, 1033–1048.
23.
CoteR. (2004) Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. International Journal of Impotence Research, 16, S28–S33.
BhandariS, KapadiA. (1983) A 9, 10-dihydrophenanthrene from tubers of Eulophia nuda. Phytochemistry, 22, 747–748.
30.
BhandariS, KapadiA, MujumderP, JoardarM, ShooleryJ. (1985) Nudol, a phenanthrene of the orchids Eulophia nuda, Eria carinata and Eria stricta. Phytochemistry, 24, 801–804.
31.
ShriramV, KumarV, KishorPK, SuryawanshiSB, UpadhyayAK, BhatMK. (2010) Cytotoxic activity of 9, 10-dihydro-2, 5-dimethoxyphenanthrene-1, 7-diol from Eulophia nuda against human cancer cells. Journal of Ethnopharmacology, 128, 251–253.
KshirsagarR, KanekarY, JagtapS, UpadhyayS, RaoR, BhujbalS, KediaJ. (2010) Phenanthrenes of Eulophia ochreata Lindl. International Journal of Green Pharmacy, 4, 147–152.
34.
DatlaP, KalluriMD, BashaK, BellaryA, KshirsagarR, KanekarY, UpadhyayS, SinghS, RajagopalV. (2010) 9, 9,10-Dihydro-2,5-dimethoxyphenanthrene-1,7-diol, from Eulophia ochreata, inhibits inflammatory signalling mediated by Toll-like receptors. British Journal of Pharmacology, 160, 1158–1170.
35.
KovácsA, VasasA, HohmannJ. (2008) Natural phenanthrenes and their biological activity. Phytochemistry, 69, 1084–1110.
